Individualization of Dosage Regimens in Obese Patients: Application to Acyclovir
NCT05589688 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2025-12-31
Summary
The number of obese people will reach 50% of the world population by 2035. Obesity is a chronic disease. For obese patients, dosage regimens have been determined for patients with a "normal" BMI between 20-30 kg/m2. Based on plasma and urine concentrations, a pharmacokinetic model will be performed to study in healthy volunteers, the predictive character of lean mass, measured by DEXA, on renal elimination and therefore on acyclovir exposure. The main objective of this study is to evaluate, in 4 volunteers groups representative of (1) non-obese (18-24.9 kg/m2), (2) overweight (25-29.9 kg/m2), (3) grade 1 obesity (30-34.9 kg/m2) and (4) grade 2 obesity (35-39.9 kg/m2), the predictive nature of lean mass, measured by DEXA, on renal elimination and therefore on acyclovir exposure.
Conditions
Interventions
- DRUG
-
Acyclovir
Subjects will receive a single dose of 5 mg/kg infused over 1 hour. Then, 13 blood samples after placement of a catheter, and 4 urine samples will be taken over the 12 hours following the start of administration
Sponsors & Collaborators
-
University Hospital, Toulouse
lead OTHER
Principal Investigators
-
Sarah Baklouti, PharmD · University Hospital, Toulouse
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-04-09
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- France
Study Locations
More Related Trials
-
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
NCT02229214 ·Status: COMPLETED ·Phase: PHASE4
-
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
NCT06144684 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3502970 in Healthy Overweight and Obese Participants
NCT05313802 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants
NCT07230496 ·Status: RECRUITING ·Phase: PHASE1
-
Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects
NCT06714825 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age
NCT02022956 ·Status: COMPLETED ·Phase: PHASE1
-
STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY
NCT04616339 ·Status: COMPLETED ·Phase: PHASE1
-
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
NCT05841238 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
NCT07291232 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
NCT06694935 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
NCT07232732 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women
NCT07224399 ·Status: RECRUITING ·Phase: PHASE1
-
To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)
NCT00482196 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
NCT06200467 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)
NCT00109148 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06693843 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity
NCT06352437 ·Status: COMPLETED ·Phase: PHASE1
-
A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)
NCT00092859 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
NCT06525935 ·Status: COMPLETED ·Phase: PHASE2
-
A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety
NCT00375401 ·Status: TERMINATED ·Phase: PHASE3
-
Arginase Inhibition in Humans With Obesity
NCT05536934 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
NCT05751226 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06683508 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106
NCT05054530 ·Status: COMPLETED ·Phase: PHASE1
-
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
NCT05035095 ·Status: COMPLETED ·Phase: PHASE3